TDC
IDXG

Thompson Davis & Co’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Thompson Davis & Co’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-200
Closed -$5K – 1232
2017
Q1 		$5K Buy
+200
New +$7.16K 0.01% 908

Other funds holding IDXG

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Thompson Davis & Co's IDXG Position: Q2 2017 in Review

Thompson Davis & Co sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q2 2017, closing a stake of 200 shares — an estimated $5K sold.

Thompson Davis & Co first reported a position in IDXG in Q1 2017 and held it in 1 quarter. The position peaked at $5K in Q1 2017. 17 funds tracked by Wall St. Rank hold IDXG as of Q2 2017.

  • Thompson Davis & Co reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 200 Interpace Biosciences, Inc. Common Stock shares in Q2 2017, an estimated $5K.
  • Thompson Davis & Co first reported a position in Interpace Biosciences, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Interpace Biosciences, Inc. Common Stock position peaked at $5K in Q1 2017.
  • 17 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.